Jinyu Bio-Technology Co (SHSE:600201) LT-Debt-to-Total-Asset: 0.00 (As of Mar. 2026)

What is Jinyu Bio-Technology Co LT-Debt-to-Total-Asset?

Jinyu Bio-Technology Co SHSE:600201 68 LT-Debt-to-Total-Asset is 0.00 as of Mar. 2026. GuruFocus rates SHSE:600201 with a GF Score™ of 68/100 and a GF Value™ of ¥8.29 (Significantly Overvalued). The stock has 5 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Jinyu Bio-Technology Co's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.00.

Jinyu Bio-Technology Co's long-term debt to total assets ratio stayed the same from Mar. 2025 (0.00) to Mar. 2026 (0.00).

Jinyu Bio-Technology Co (SHSE:600201) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Jinyu Bio-Technology Co LT-Debt-to-Total-Asset Related Terms

Jinyu Bio-Technology Co LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Jinyu Bio-Technology Co's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jinyu Bio-Technology Co LT-Debt-to-Total-Asset Chart

Jinyu Bio-Technology Co Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.00

Jinyu Bio-Technology Co Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.00	0.00	0.00	0.00	0.00

68GF Score

Jinyu Bio-Technology Co Ltd SHSE:600201

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Jinyu Bio-Technology Co LT-Debt-to-Total-Asset Calculation

Jinyu Bio-Technology Co's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )	/	Total Assets (A: Dec. 2025 )
	=	0.147	/	6611.572
	=	0.00

Jinyu Bio-Technology Co's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )	/	Total Assets (Q: Mar. 2026 )
	=	0.148	/	6536.935
	=	0.00

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.00 mean?

Jinyu Bio-Technology Co (SHSE:600201) has a LT-Debt-to-Total-Asset of 0.00 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Jinyu Bio-Technology Co and its competitors.

Is Jinyu Bio-Technology Co's LT-Debt-to-Total-Asset too high?

Jinyu Bio-Technology Co's current LT-Debt-to-Total-Asset is 0.00. Overall, Jinyu Bio-Technology Co has a GF Score™ of 68/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Jinyu Bio-Technology Co's LT-Debt-to-Total-Asset compare to VRTX and REGN?

Jinyu Bio-Technology Co's LT-Debt-to-Total-Asset of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Biotechnology company?

A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Jinyu Bio-Technology Co and its competitors. Jinyu Bio-Technology Co's current LT-Debt-to-Total-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Jinyu Bio-Technology Co stock overvalued right now?

Based on GuruFocus' analysis, Jinyu Bio-Technology Co (SHSE:600201) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥8.29, compared to a current price of ¥12.18 — trading 46.9% above its estimated fair value. The current LT-Debt-to-Total-Asset is 0.00. Jinyu Bio-Technology Co's overall GF Score™ is 68/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Jinyu Bio-Technology Co (SHSE:600201), the current LT-Debt-to-Total-Asset is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Jinyu Bio-Technology Co (SHSE:600201) Overvalued in 2026?

Based on GuruFocus' analysis, Jinyu Bio-Technology Co stock appears to be overvalued. The current stock price of ¥12.18 is trading 46.9% above its estimated GF Value™ of ¥8.29. GuruFocus considers Jinyu Bio-Technology Co to be Significantly Overvalued.

Key valuation signals for SHSE:600201:

LT-Debt-to-Total-Asset: 0.00
GF Value™: ¥8.29 vs. price of ¥12.18 (46.9% above fair value)
GF Score™: 68/100 with 5 warning signs

No single metric tells the full story. See the SHSE:600201 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Jinyu Bio-Technology Co Business Description

Industry Healthcare Biotechnology

Comparable Companies SHSE:688759 SZSE:300009 SHSE:688222 SZSE:300497 BJSE:920982 SZSE:002287 SHSE:688166 SHSE:688062 SZSE:000990 SHSE:688319 VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Address No.1, Jinyu Street, Shaeryu Industrial Park, Economic and Technological Development Zone, Inner Mongolia Autonomous Region, Hohhot, CHN, 010030

Website http://www.jinyu.com.cn

Jinyu Bio-Technology Co Ltd is engaged in the development and sales of veterinary biological products. Its products are used for pigs, poultry, pets, and ruminants.

68GF Score

Get the complete analysis for SHSE:600201

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥12.18

Price

¥8.29

GF Value

View SHSE:600201 Analysis

See LT-Debt-to-Total-Asset data for all stocks →